Amgen Inc., et al., Petitioners v. Sanofi, et al.

  1. February 21, 2023

    Justices Let SG Join Amgen Case, But Not Chemistry Group

    The U.S. Supreme Court on Tuesday cleared the government to participate alongside Sanofi and Regeneron in upcoming oral arguments over patent enablement, but refused an arm of the American Chemical Society's uninvited attempt to join Amgen.

  2. February 13, 2023

    Feds, Nobel Prize Winner Back Sanofi At High Court IP Fight

    The federal government, various drug companies and a molecular biologist who won the Nobel Prize for his work with monoclonal antibodies urged the U.S. Supreme Court to keep the standard of patent enablement as is, backing Sanofi and Regeneron in their fight against Amgen.

  3. February 03, 2023

    Sanofi Urges Justices To Deny Amgen's 'Monopoly' Attempt

    Sanofi and Regeneron on Friday urged the U.S. Supreme Court to reject Amgen's arguments that it deserves broad patent coverage on cholesterol drugs the rivals both sell, in the one patent case the justices have agreed to hear this term.

  4. January 05, 2023

    Amgen Doesn't Want Chemistry Group's Help At High Court

    Amgen Inc. on Thursday urged the U.S. Supreme Court to deny a chemistry organization's request to speak at oral arguments in a high-profile fight over the standard for a patent to meet enablement requirements.

  5. January 03, 2023

    Amgen Gets Broad Support In High Court Patent Fight

    Massive drug companies, early-stage startups and a wide range of intellectual property groups were among many parties Tuesday urging the U.S. Supreme Court to hold that the Federal Circuit erred when invalidating Amgen patents in a fight over how to interpret when a patent meets enablement requirements.

  6. January 02, 2023

    Patent Cases To Watch In 2023

     The Supreme Court's foray into what it takes to enable someone to make a patented invention, the patent infringement implications of labels on generic drugs and a dispute over which arguments can be in court following an inter partes review are among the patent cases attorneys will be tracking this year.

  7. November 10, 2022

    Justices Seem Less Receptive To SG's Take On IP Cases

    The U.S. Supreme Court has decided to review a patent case about enablement that the solicitor general explicitly recommended against, a move attorneys found surprising, especially given the justices' unprecedented decision to deny a patent eligibility case the government backed just months before.

  8. November 04, 2022

    Supreme Court Will Tackle Patent Enablement In Amgen Case

    The U.S. Supreme Court on Friday agreed to review Section 112 of the Patent Act for the second time in the law's history, accepting Amgen's request to consider how much a patent must disclose in order to meet enablement requirements.

  9. October 05, 2022

    SG's Take On Patent Enablement Seen As An Expansion

    In urging the U.S. Supreme Court to reject an appeal by Amgen involving the patent enablement requirement, the U.S. solicitor general has stated an expansive view of the provision that may be impossible for some inventions to meet, experts say.

  10. September 22, 2022

    SG Tells Justices To Reject Amgen Patent Enablement Case

    The U.S. solicitor general says that the U.S. Supreme Court should not consider Amgen's appeal of a Federal Circuit decision tossing its jury win against Sanofi and Regeneron Pharmaceuticals Inc. over two antibody patents on its cholesterol medication Repatha.